Cambridge-based Ingenia Therapeutics, a biotechnology company developing a therapeutic antibody candidate for capillary diseases recently closed a $7 million venture capital round, per an SEC filing. Terms of the round were not disclosed.
Company will use this funding to accelerate business growth.
Ingenia is a privately held biotechnology company specializing in the discovery and development of therapeutic antibody candidates for patient populations suffering from defective micro-vessel and progressive chronic diseases.
Currently, Ingenia focuses on the treatment of damaged capillary-associated indications with high unmet clinical needs and has exclusive global rights to develop therapeutic antibody candidates for restoring damaged capillaries to their healthy state by modulating endothelial cell signaling pathways to recover damaged capillary functions.
Ingenia builds on strategic research partnerships with major pharmaceutical companies for research and development activities to deliver human proof of concept studies.
